



# 24<sup>TH</sup> EUROPEAN MEETING ON HIV & HEPATITIS 2026

TREATMENT STRATEGIES & ANTIVIRAL DRUG RESISTANCE

BARCELONA, SPAIN | 10-12 JUNE 2026

01/04/2026

## Wednesday, June 10

### Opening of the HIV & Hep Workshop

CEST

14:00 Opening Words

Chairs

14:05 Welcome to Barcelona

### Session 1: CROI 2026 Resistance

speakers

#### Session chairs

14:15 CROI Resistance Summary Lecture 1 - Basic Science

**Charlotte Carpentier**, PharmD, PhD

Hôpital Bichat-Claude Bernard, France

14:30 CROI Resistance Summary Lecture 2 - Clinical Science

**Mitosz Parczewski**, MD, PhD

Pomeranian Medical University, Szczecin, Poland

14:45 WHO Integrated Drug Resistance Action Framework 2026-2030

**Michael Jordan**, MD, MPH

Tufts University School of Medicine, Boston, US

15:00 Panel Discussion:

15:45 Coffee Break

### Session 2: Epidemiology Trends - STI / HIV/ vHep

speakers

#### Session chairs:

16:15 *Diverging HIV-1 Variant Trends across the Who European Subregions*

**Karol Serwin**

16:25 *HIV-1 sub-subtype A6 epidemic in Italy: characteristics and phylogenetic analysis*

**Alessia Lai**

16:35 *Two Faces of an Epidemic: Distinct Clinical and Molecular Profile of Hiv-1 Infection among Msm and Heterosexual Individuals in Cyprus, 2021-2025*

**Eirini Hadjioannou**

16:45 **Round Table: Migration as a Driver of Population Health Change in Europe**

*Situation in Central and Eastern Europe (migration from Ukraine)*

**Tetiana Melnyk**, PhD

National Pirogov Memorial Medical University, Ukraine

*Situation in South Europe (migration from Africa)*

**Nicola Coppola**, MD

University of Campania, Italy

*Situation in Western Europe (migration from Asia)*

**Fiona Bruns**, PhD, FRCP

Royal Free Hospital London, UK

17:30 **Guided Poster Tour 1:**

< Poster presenters will be strictly limited to 4 minutes to describe their poster.>

**Francesca Ceccherini Silberstein**, PhD

University of Rome "Tor Vergata", Italy

18:25 Networking Reception

## Thursday, June 11

### Session 3: Biomarkers for Viral Infections

#### Session chairs:

08:30 HIV DNA as a Biomarker - Ready for the Clinic?

**Maria Santoro, PhD**

University of Rome "Tor Vergata", Italy

08:45 Role of Novel Biomarkers for HBV-HDV

**Valentina Svicher, PhD**

University of Rome "Tor Vergata", Italy

09:00 HBsAg isoforms vary according to HDV subgenotypes and their levels distinguish the different disease stages of chronic HDV infection

**Stefano D'Anna**

09:10 Integrating Neurocognitive Assessment and Plasma Proteomics to Identify Biomarkers of Neurocognitive Impairment in Aging People With HIV

**Iris Teubel**

09:20 Discussion

### Session 4: What's in the HIV Pipeline? Presentations on Future Viral Therapeutics

#### speakers

#### Session chairs:

09:30 Gilead Sciences

**Martin Rhee, MD**

Gilead Sciences, San Mateo, California, US

09:45 ViiV Healthcare

**Jean van Wyk, MD, ChB**

ViiV Healthcare, London, UK

10:00 Merck-MSD

**Rafael Campo, MD**

MSD, North Wales, Pennsylvania, US

10:15 Discussion

10:30 Coffee Break & Poster Viewing Odd-numbered posters

### Session 5: Low level viremia, What is it and What do we do with it?"

#### speakers

#### Session chairs:

11:00 Detecting it - How Low can we go - Viral Load / Resistance

**Anne Genevieve Marcelin, MD**

Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France

11:15 What to do - Clinical Perspective

**Huldrych Gunthard, MD**

University Hospital Zürich, Switzerland

11:30 Impact of LLV on Viral Evolution

**Roger Paredes, MD, PhD**

Hospital Germans Trias & IrsiCaixa AIDS Research Institute, Spain

11:45 Discussion

### Pharma-Supported Symposium - ViiV HealthCare

12:15

13:00 Lunch

### Pharma-Supported Symposium - MSD

14:00

### Session 6: Abstract Driven Session

#### speakers

#### Session chairs:

14:45 Changes in HIV-1 Reservoirs in Virologically Suppressed People with HIV-1 One Year After Receiving Lenacapavir and the Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab

**Laurie VanderVeen**

14:55 Multidisciplinary assessment of the HIV-1 reservoir after switching from triple to dual antiretroviral therapy in virologically suppressed individuals, a prospective observational pilot study.

**Niccolò Bartolini**

15:05 Automated Real-Time Molecular Surveillance Platform Reveals HIV-1 Drug Resistance Dynamics and Transmission Cluster Origins among Msm across Europe

**Beatriz Valadas**

15:15 Relevance and Value of Sequencing the 5' Leader Region of HIV-1 in Plasma in Clinical Practice

**Marc Wirden**

15:25 Added Value of RNA-Based Whole Genome Sequencing in Viremic People with 4-Class Drug-Resistant HIV: Insights from the PRESTIGIO Registry

**Tommaso Clemente**

15:35 Evaluation of HIV-1 Integrase Resistance Patterns and Associated Clinical Factors in individuals who failed dolutegravir containing regimens in Cameroon

**Collins Ambe Chenwi**

15:45 Discussion

16:00 Coffee Break & Poster Viewing Even-numbered posters

### Session 7: Clinical Considerations using Long Acting Antivirals

#### Session chairs:

16:30 bNAb Resistance - Detection & Implication

**Bob Shafer,**

Stanford, Palo Alto, California, US

16:45 Use of LA - ART in Challenging Patients

**Sanjay Bhagani, BSc, FRCP**

Consultant Physician in Infectious Diseases/HIV Medicine and General (internal) Medicine, Royal Free Hospital. London. UK

17:00 TDM for CAB/RPV in Failing Patients - The Swiss Approach

**Catia Marzolini, PharmD, PhD**

University Hospital of Basel, University Hospital of

Lausanne. Switzerland

17:15 TDM for CAB/RPV in Failing Patients - The Spanish Approach

**Jose Molto, MD, PhD**

Hospital Universitari Germans Trias i Pujol, Spain

17:30 Discussion

---

17:45 **End of the Plenary Program**

---

17:45 **Guided Poster Tour 2 -**

*< Poster presenters will be strictly limited to 4 minutes to describe their poster.>*

**Federico Garcia, PharmD, PhD**  
*Hospital Universitario San Cecilio, Spain*

20:00 **Networking Dinner**

---

---

## Friday, June 12

### Session 8: Hepatitis Related Session

#### Session chairs:

09:00 **Hepatitis Treatment** - Overview on the Different Modes of Actions

**Stanilas Pol**, MD, PhD  
Hôpital Cochin, Paris, France

09:15 **Hepatitis Pipeline** - What is Coming

**Sabela Lens**, MD  
Hospital Clinic, Institut d'Investigacions Biomèdiques  
August Pi i Sunyer, Barcelona, Spain

09:30 **Hepatitis Delta in Spain: Nationwide Prevalence and Comprehensive Clinical and Virological Characterization**

**Ana Alberola Romano**

09:40 **Hepatitis Delta antigen and ribozyme genetic variability is associated with altered virological and biochemical markers and provides basis for the identification of novel therapeutic targets**

**Alessia Magnapera**

09:50 **Acute Hepatitis B Cluster Among MSM: Possible Concerns on New ART and PrEP Strategies**

**Rémi Rouget**

10:00 *Discussion*

10:20 **Coffee Break**

### Session 9: Controversies in Clinical Virology - the Impact of Polymorphisms

#### Session chairs:

10:50 **Detecting APOBEC Driven Variation** - How do you determine/detect APOBEC Variation

**Martin Obermeier**, MD  
German Heart Centre Berlin (DHZB) / Medical Centre for  
Infectious Diseases in Berlin MVZ mbH AG, Germany

11:10 **What is the Clinical Implications of APOBEC Driven Variation** - What do you do with it in the Clinic

**Anne Maria Geretti**, MD, PhD, FRCPATH  
University of Rome, Italy / King's College London, UK

11:30 **Characterization of Intrinsic Susceptibility to APOBEC3-Mediated G-To-a Transitions across the Hiv-1 Mutational Landscape: Implications for Capsid and Enzymatic Targets**

**Hossein Elzadi-Moghadam**

11:40 **Contribution of Plasma Next-Generation Sequencing to Resistance Assessment at Virological Failure Compared with Cumulative Historical Genotypes: Data from the ARCA Cohort and the Italian NGS**

**Daniele Armenia**

11:50 *Discussion*

12:20 **Lunch**

### Session 10: HIV Drug Resistance - Complex Interpretation

#### Session chairs:

13:20 **Regimen Potency - Regimen-Specific Resistance Risks**

**Josep Llibre**, MD, PhD  
Fundació Lluita contra la Sida; Hospital Universitari  
Germans Trias i Pujol, Spain

13:40 **Second Generation INSTI resistance - Noncanonical Resistance Mutations**

**Francesca Ceccherini Silberstein**, PhD  
University of Rome "Tor Vergata", Italy

14:20 **Interpretation of "Historical" Genotypes - Plasma & DNA**

**Federico Garcia**, PharmD, PhD  
Hospital Universitario San Cecilio, Spain

14:40 *Discussion*

15:00 **Closure of the Workshop**

15:00 **End of the Meeting**